Trilaciclib (G1T28): A cyclin dependent kinase 4/6 inhibitor, in combination with etoposide and carboplatin (EP) for extensive stage small cell lung cancer (ES-SCLC) -Phase 1b results.

被引：6
|
作者：
Lima, Caio Max S. Rocha
Roberts, Patrick J.
Priego, Victor M.
Divers, Stephen G.
Thomas, Melanie B.
Boccia, Ralph V.
Stabler, Katie
Andrews, Elizabeth
Malik, Rajesh K.
Aljumaily, Raid
Hamm, John Turner
Chiu, Vi Kien
Richards, Donald A.
Nikolinakos, Petros
Hussein, Maen A.
Schuster, Steven Robert
Hoyer, Robert John
Shapiro, Geoffrey
Dragnev, Konstantin H.
Owonikoko, Taofeek Kunle
机构：
[1] Gibbs Canc Ctr & Res Inst, Spartanburg, SC USA
[2] G1 Therapeut Inc, Res Triangle Pk, NC USA
[3] Ctr Canc & Blood Disorders, Bethesda, MD USA
[4] Genesis Canc Ctr, Hot Springs, AR USA
[5] Med Univ South Carolina, Charleston, SC 29425 USA
[6] PPD, Wilmington, NC USA
[7] Univ Oklahoma, Med Ctr, Oklahoma City, OK USA
[8] Norton Healthcare, Louisville, KY USA
[9] Univ New Mexico, Comprehens Canc Ctr, Albuquerque, NM 87131 USA
[10] Texas Oncol, Tyler, TX USA
[11] Univ Canc & Blood Ctr LLC, Athens, GA USA
[12] Florida Canc Specialists & Res Inst, Leesburg, FL USA
[13] Univ Colorado, Ft Collins, CO USA
[14] Mem Sloan Kettering Canc Ctr, Colorado Springs, CO USA
[15] Dana Farber Canc Inst, Boston, MA 02115 USA
[16] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA
[17] Emory Univ, Atlanta, GA 30322 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.8568
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8568
引用
收藏
页数：5
相关论文
共 50 条
  • [1] G1T28, a cyclin dependent kinase 4/6 inhibitor, in combination with etoposide and carboplatin for extensive stage small cell lung cancer (ES-SCLC): preliminary results
    Lima, Caio Max S. Rocha
    Roberts, Patrick J.
    Priego, Victor M.
    Divers, Stephen G.
    Thomas, Melanie
    Boccia, Ralph
    Webb, R. Timothy
    Stabler, Katie
    Makhuli, Karenann M.
    Malik, Rajesh
    Aljumaily, Raid
    CANCER RESEARCH, 2016, 76
  • [2] G1T28, a Cyclin Dependent Kinase 4/6 Inhibitor, in Combination with Topotecan for Previously Treated Small Cell Lung Cancer: Preliminary Results
    Hart, Lowell
    Roberts, Patrick
    Ferrarotto, Renata
    Bordoni, Rodolfo
    Conkling, Paul
    Pati, Tejas
    Lima, Caio Max Rocha
    Owonikoko, Taofeek
    Schuster, Steven
    Jotte, Robert
    Hoyer, Robert
    Stabler, Katie
    Makhuli, Karen
    Aljumaily, Raid
    Edenfield, William
    Spira, Alexander
    Malik, Rajesh
    Shapiro, Geoffrey
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S696 - S696
  • [3] Carfilzomib (CFZ), carboplatin and etoposide for previously untreated extensive-stage small cell lung cancer (ES-SCLC): Phase 1b results from a phase 1b/2 study.
    Badin, Firas Benyamine
    Chiang, Anne C.
    Fisher, William B.
    Orlov, Sergey
    Harper, Harry D.
    Eskander, Elhamy
    Harb, Wael A.
    Kio, Ebenezer
    Gopalan, Priya Kadambi
    Haggstrom, Daniel Ernest
    Burdaeva, Olga
    Zahlten-Kumeli, Anita
    Aggarwal, Sanjay
    Obreja, Mihaela
    Gorbunova, Vera
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] A phase Ib trial of Bcl-2 inhibitor obatoclax in combination with carboplatin and etoposide for previously untreated patients with extensive-stage small cell lung cancer (ES-SCLC)
    Chiappori, A.
    Schreeder, M. T.
    Moezi, M. M.
    Stephenson, J.
    Blakely, J. L.
    Salgia, R.
    Chu, Q. S.
    Malik, S. M.
    Modiano, M. M.
    Berger, M. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] Phase I trial of the hedgehog (Hh) inhibitor, LDE225, in combination with etoposide and cisplatin (EP) for initial treatment of extensive stage small cell lung cancer (ES-SCLC)
    Pietanza, Maria Catherine
    Krug, Lee M.
    Varghese, Anna M.
    Fleisher, Martin
    Teitcher, Jerrold B.
    Holodny, Andrei
    Sima, Camelia S.
    Litvak, Anna Maria
    Ng, Kenneth K.
    Patel, Payal R.
    Ibrahim, Fawzia
    Haughney-Siller, Anne
    Dulko, Dorothy
    Monger, Grace
    Albano, Melanie
    Moran, Clare M.
    Kris, Mark G.
    Rudin, Charles M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] CALGB 30103: A randomized phase II study of carboplatin and etoposide (CE) with or without G3139 in patients with extensive stage small cell lung cancer (ES-SCLC).
    Rudin, CM
    Salgia, R
    Wang, XF
    Green, MR
    Vokes, EE
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 662S - 662S
  • [7] A Phase I Study of Pomalidamide (CC-4047) in Combination With Cisplatin and Etoposide in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
    Ellis, P. M.
    Zhang, J.
    Jones, M.
    Jungnelius, U.
    Shepherd, F. A.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S551 - S551
  • [8] A phase II trial of carboplatin and irinotecan as first-line therapy for extensive stage small cell lung cancer (ES-SCLC): Preliminary results
    Laskin, J
    Shirley, B
    Dobbs, T
    Bi, J
    Carbone, D
    Johnson, D
    Sandler, A
    LUNG CANCER, 2005, 49 : S323 - S323
  • [9] Results from a randomized study of carboplatin and etoposide (CE) with or without palifosfamide (Pa) in extensive stage small cell lung cancer (ES-SCLC): The MATISSE study.
    Jalal, Shadia Ibrahim
    Einhorn, Lawrence H.
    Lo, Gregory
    Lavin, Philip
    Lebel, Francois M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [10] Phase 1b trial of two schedules of the BCL-2 inhibitor obatoclax in combination with carboplatin and etoposide for patients with extensive stage small cell lung cancer (ESSCLC)
    Chiappori, Alberto A.
    Schreeder, Marshall T.
    Moetzi, Mehdi M.
    Stephenson, Joe
    Blakely, Johnetta L.
    Salgia, Ravi
    Chu, Quincy S.
    Hermann, Robert
    Subramaniam, Deepa
    Modiano, Manuel
    Richards, Donald
    Ross, Helen J.
    Berger, Mark S.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S393 - S394
12345